667, L.P.
CIK 1551139 · last filed 2026-06-29
667, L.P. is a corporate insider who has filed 88 SEC Form 4 insider transactions across 24 companies since 2013. The most recent filing, for CELC, was dated Jul 14, 2026. Across all open-market trades the lifetime net is +$5.23B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.75B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.75B
24
88
$5.23B
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VTVT | Director | — | $31.08 | — | $0 | 2 | 2026-06-29 |
| ACAD | Director | 39,487,463 | $26.01 | $1.03B | $630.00M | 3 | 2026-06-02 |
| ONC | Director | 730,643 | $330.46 | $241.45M | -$1.57M | 2 | 2026-05-27 |
| TCRX | Director | — | $0.77 | — | $0 | 3 | 2026-05-22 |
| INCY | Director | 28,482,491 | $129.93 | $3.70B | $0 | 11 | 2026-05-11 |
| REPL | Director | — | $5.35 | — | $0 | 1 | 2026-04-07 |
| DBVT | Director | — | $13.50 | — | $0 | 1 | 2026-01-14 |
| KOD | Director | 18,358,772 | $40.29 | $739.67M | $650.35M | 7 | 2025-12-19 |
| DNLI | Director | — | $24.05 | — | $0 | 1 | 2025-12-15 |
| MDGL | Director | 1,832,216 | $538.80 | $987.20M | $196.74M | 3 | 2025-08-20 |
| IMCR | Director | — | $33.51 | — | $0 | 1 | 2025-05-19 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 355,142 | $1.27 | $451.0K | $0 | 9 | 2025-01-03 |
| BCYC | Director | 8,666,247 | $3.94 | $34.15M | $127.38M | 2 | 2024-12-17 |
| PRLD | Director | — | $4.64 | — | $0 | 2 | 2024-06-18 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 126,096 | $184.71 | $23.29M | $3.77B | 2 | 2024-06-07 |
| NGNE | Director | 39,081 | $33.22 | $1.30M | $0 | 1 | 2023-12-20 |
| Talis Biomedical Corp (TLIS) Delisted | Director | — | $2.84 | — | $0 | 1 | 2023-06-13 |
| KNSA | Director | 132,566 | $79.44 | $10.53M | $0 | 2 | 2023-06-08 |
| Seagen Inc. (SGEN) Delisted | Director | 43,000,581 | $228.74 | $9.84B | $180.65M | 5 | 2023-06-02 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 1 | 2021-05-13 |
| ZYME | Director | — | $22.61 | — | $0 | 1 | 2020-05-12 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 157,519 | — | — | -$482.48M | 10 | 2019-04-12 |
| Aceragen, Inc. (IDRA) Delisted | Director | 9,088 | $7.22 | $65.7K | $224.00M | 4 | 2018-06-21 |
| XOMA | Director | 104,451 | $40.17 | $4.20M | -$59.06M | 1 | 2015-01-06 |
Recent Filings
88 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-14 | CELC | Notice (144) | −261,368 | -$26.79M | EDGAR |
| 2026-06-29 | VTVT | Grant (A) | — | $0 | EDGAR |
| 2026-06-02 | ACAD | Grant (A) | +223,464 | $0 | EDGAR |
| 2026-05-27 | ONC | Sell (S) | −65,988 | -$1.57M | EDGAR |
| 2026-05-22 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2026-05-11 | INCY | Exer (M) | +180,000 | $15.22M | EDGAR |
| 2026-04-23 | TARA | Notice (144) | −24,802 | -$132.7K | EDGAR |
| 2026-04-07 | REPL | Grant (A) | — | $0 | EDGAR |
| 2026-03-06 | TARA | Notice (144) | −38,277 | -$223.9K | EDGAR |
| 2026-03-04 | TARA | Notice (144) | −35,173 | -$220.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.